Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hasan Khosravi

Dermatology Chicago, IL Medical Doctor

NPI 1649790627 CMS profile 3310360

808 S Wood St Ste 380, Chicago, IL 60612

Open in the dashboard

General payments

$12,008

622 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hasan Khosravi of Chicago, IL is reported in the CMS Open Payments database as having received $12,008 across 622 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,672 131
2024 General $3,659 181
2023 General $3,065 166
2022 General $2,088 134
2021 General $524 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hasan Khosravi
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Hasan Khosravi were reported at $2,672. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Hasan Khosravi Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $524 $377 $108–$1,108 $132
2022 $2,088 $514 $143–$1,391 $149
2023 $3,065 $607 $159–$1,674 $160
2024 $3,659 $751 $204–$1,903 $164
2025 $2,672 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,095 119 payments
  2. Sun Pharmaceutical Industries Inc. $904 58 payments
  3. Pfizer Inc. $836 54 payments
  4. UCB, Inc. $800 34 payments
  5. Janssen Biotech, Inc. $800 33 payments
  6. Novartis Pharmaceuticals Corporation $777 39 payments
  7. Genzyme Corporation $743 29 payments
  8. E.R. Squibb & Sons, L.L.C. $644 40 payments
  9. Incyte Corporation $640 34 payments
  10. Regeneron Healthcare Solutions, Inc. $528 18 payments
  11. Other $3,241 164 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,847 619 payments
  2. Education $161 3 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $968 54 payments
  2. CIBINQO $820 53 payments
  3. SKYRIZI $772 40 payments
  4. TREMFYA $757 28 payments
  5. Bimzelx $711 30 payments
  6. ILUMYA $701 47 payments
  7. SOTYKTU $644 40 payments
  8. OPZELURA $640 34 payments
  9. COSENTYX $619 32 payments
  10. EUCRISA $603 42 payments
  11. Other $5,906 299 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

354

Median for Dermatology: 534

Drug cost

$7,935

Median for Dermatology: $67,151

Branded share of claims

9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 54 $3,450
Tretinoin Generic 20 $1,249
Triamcinolone Acetonide Generic 69 $752
Clindamycin Phosphate Generic 18 $714
Valacyclovir Valacyclovir Hcl Brand 32 $466
Mometasone Furoate Generic 12 $321
Ketoconazole Generic 29 $308
Hydrocortisone Generic 56 $290
Minoxidil Generic 22 $150
Mupirocin Generic 20 $120

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $351
$351 — —
TREMFYA
  • Janssen Biotech, Inc. $342
$342 — —
DUPIXENT
  • GENZYME CORPORATION $171
  • Regeneron Healthcare Solutions, Inc. $137
$308 — —
VTAMA
  • Dermavant Sciences, Inc. $246
$246 — —
RINVOQ
  • AbbVie, Inc. $245
$245 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

622 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record